{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:52:43Z","timestamp":1761486763888},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6429,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,6]]},"DOI":"10.1093\/annonc\/mdf133","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T19:00:51Z","timestamp":1027710051000},"page":"866-873","source":"Crossref","is-referenced-by-count":24,"title":["Addition of either irinotecan or methotrexate to bolus5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group"],"prefix":"10.1016","volume":"13","author":[{"given":"P.","family":"Comella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Crucitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"De Lucia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Farris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Del Gaizo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Palmeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Iannelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mancarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tafuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Maiorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Buzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"De Cataldis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdf133_bb0010","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0959-8049(99)00314-7","article-title":"New directions in the treatment of colorectal cancer a look to the future","volume":"36","author":"Sobrero","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdf133_bb0015","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1200\/JCO.1992.10.6.896","article-title":"Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate","volume":"10","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf133_bb0020","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1200\/JCO.1994.12.5.960","article-title":"Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer","volume":"12","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf133_bb0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/030089169908500608","article-title":"Concurrent modulation of 5-fluorouracil with methotrexate and l-leucovorin: An effective and moderately toxic regimen for the treatment of advanced colorectal carcinoma. A multicenter phase II study of the Southern Italy Cooperative Oncology Group","volume":"85","author":"Comella","year":"1999","journal-title":"Tumori"},{"key":"10.1093\/annonc\/mdf133_bb0030","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/1097-0142(19950315)75:6<1238::AID-CNCR2820750605>3.0.CO;2-P","article-title":"Sequential methotrexate, 5-fluorouracil (5-FU), and high-dose leucovorin versus 5-FU and high-dose leucovorin versus 5-FU alone for advanced colorectal cancer","volume":"75","author":"Abad","year":"1995","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf133_bb0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/oxfordjournals.annonc.a058463","article-title":"Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer","volume":"4","author":"Glimelius","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf133_bb0040","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s002800050485","article-title":"Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial","volume":"38","author":"Polyzos","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdf133_bb0045","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1023\/A:1026527605389","article-title":"Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study","volume":"11","author":"Sobrero","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf133_bb0050","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdf133_bb0055","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer","volume":"352","author":"Cunningham","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdf133_bb0060","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdf133_bb0065","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer. A multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdf133_bb0070","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1023\/A:1008339010655","article-title":"Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group","volume":"10","author":"Comella","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf133_bb0075","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1023\/A:1008375705484","article-title":"Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II\u2013III randomized study","volume":"11","author":"Comella","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf133_bb0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf133_bb0085","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<729::AID-IJC20>3.0.CO;2-#","article-title":"Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT29 in vitro and in vivo","volume":"27","author":"Guichard","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdf133_bb0090","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2307\/2531495","article-title":"A two-stage design for choosing among experimental treatments and a control in clinical trials","volume":"45","author":"Thall","year":"1989","journal-title":"Biometrics"},{"key":"10.1093\/annonc\/mdf133_bb0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"11","key":"10.1093\/annonc\/mdf133_bb0100","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/0277-5379(86)90133-1","article-title":"Significance testing in comparison of survival curves from clinical trials of cancer treatment","author":"Haybittle","year":"1986","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1093\/annonc\/mdf133_bb0105","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s002800050835","article-title":"Effect of adding topoisomerase I poison 7-ethyl-10-hydrossycamtpthecin (SN-38) to 5-fluorouracil and folinic acid in HCT8 cells: elevated dTTP pools and enhanced cytotoxicity","volume":"42","author":"Mullany","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdf133_bb0110","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0959-8049(99)00222-1","article-title":"Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines","volume":"35","author":"Mans","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdf133_bb0115","first-page":"3717","article-title":"Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose","volume":"60","author":"Cao","year":"2000","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdf133_bb0120","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJM200107123450213","article-title":"Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer","volume":"345","author":"Sargent","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419634769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419634769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/6\/866\/587353\/mdf133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T02:32:02Z","timestamp":1582165922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419634769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["S0923753419634769"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf133","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,6]]}}}